Hepatic impairment No dose adjustment is needed in sufferers with gentle or moderate (Little one-Pugh A or B) hepatic impairment (see section 5.two). Exposure to midostaurin and its Energetic metabolite CGP62221 is significantly decrease in patients with critical hepatic impairment than that in individuals with usual hepatic functionality (see segment https://toddx073ash0.onzeblog.com/profile